BeStock  
Stocks › Medical Devices › AORT

Artivion AORT

US equityMarket cap rank #3235Medical Devices
$18.16 −$0.37 (-2.00%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $18.16 0.00%
Open$18.52
Prev close$18.53
Day range$18.13 – $18.93
Volume642.1K
Market cap$886.02M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$123.79M+9.2% YoY
Operating profit$2.95M-67.4% YoY
Net profit-$7.93M-221.9% YoY
Diluted EPS-$0.16-223.1% YoY
Free cash flow-$17.57M-199.5% YoY
Operating cash flow-$4.56M

Revenue, last 8 quarters

$97.3MDec '24$99.0MMar '25$113.0MJun '25$113.4MSep '25$116.0MDec '25$116.3MMar '26$125.8MJun '26$123.8MSep '26

Net profit, last 8 quarters

$-16.5MDec '24$-505.0KMar '25$1.3MJun '25$6.5MSep '25$2.4MDec '25$1.4MMar '26$-13.5MJun '26$-7.9MSep '26

Diluted EPS by quarter

-0.39Dec '24-0.01Mar '250.03Jun '250.13Sep '250.05Dec '250.03Mar '26-0.28Jun '26-0.16Sep '26

Free cash flow by quarter

$8.7MDec '24$-20.6MMar '25$11.7MJun '25$17.7MSep '25$-7.9MDec '25$-6.8MMar '26$-12.0MJun '26$-17.6MSep '26

Annual revenue

$253.2MFY20$298.8MFY21$313.8MFY22$354.0MFY23$388.5MFY24$441.3MFY25

Profitability & balance sheet

Gross margin63.3%
Operating margin1.6%
Net margin-3.6%
Return on equity-4.0%
Return on assets-1.8%
Return on invested capital-0.3%
Current ratio4.42
Liabilities / assets57.2%
Cash & investments$48.40M
Total debt$401.08M
Net cash (debt)-$352.68M

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Medical devices$98.16M 79.3%
  • Preservation services$25.63M 20.7%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $123.79M $125.76M $116.34M $441.33M $115.99M
Total Operating Revenue $123.79M $125.76M $116.34M $441.33M $115.99M
Cost of Revenue $47.81M $45.24M $40.89M $157.10M $42.85M
Gross Profit $75.98M $80.52M $75.45M $284.23M $73.14M
Operating Expense $73.03M $88.88M $69.66M $257.48M $65.96M
Selling and Admin Expenses $63.22M $79.83M $60.82M $226.49M $56.84M
Research & Development $9.81M $9.06M $8.84M $30.99M $9.12M
Operating Profit $2.95M -$8.36M $5.79M $26.75M $7.18M
Net Non-Operating Interest Income (Expense) -$8.42M -$6.89M -$5.16M -$25.82M -$5.22M
Non-Operating Interest Income $102,000.00 $367,000.00 $205,000.00 $763,000.00 $311,000.00
Non-Operating Interest Expense $8.52M $7.25M $5.37M $26.58M $5.53M
Other Income (Expense) -$451,000.00 $3.55M -$286,000.00 $13.85M $4.58M
Special Income (Charges) $0.00 $0.00 – $4.34M $3.50M
-Gain on Sale of Property/Plant/Equipment $0.00 – – $7.00M $3.50M
Other Non-Operating Income (Expenses) -$451,000.00 $3.55M -$286,000.00 $9.52M $1.08M
Pretax Profit -$5.92M -$11.70M $339,000.00 $14.78M $6.54M
Tax $2.01M $1.81M -$1.08M $5.01M $4.11M
Net Profit -$7.93M -$13.51M $1.42M $9.77M $2.43M
Profit from Continuing Operations -$7.93M -$13.51M $1.42M $9.77M $2.43M
Net Income to Parent Company -$7.93M -$13.51M $1.42M $9.77M $2.43M
Other Preferred Stock Dividends -$10,000.00 -$16,000.00 $1,000.00 $11,000.00 $2,000.00
Net Income to Common Stockholders -$7.92M -$13.49M $1.42M $9.76M $2.42M
Basic EPS -$0.16 -$0.28 $0.03 $0.22 $0.05
Diluted EPS -$0.16 -$0.28 $0.03 $0.21 $0.05
Dividend Per Share $0.00 $0.00 $0.00 $0.00 $0.00
-Less:Other Special Charges – – – $2.66M $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.04B $1.07B $883.16M $884.80M $884.80M
Total Current Assets $338.81M $371.38M $357.52M $358.08M $358.08M
Cash and Cash Equivalents & Short-Term Investments $48.40M $77.32M $55.76M $64.91M $64.91M
-Cash and Cash Equivalents $48.40M $77.32M $55.76M $64.91M $64.91M
Receivables $106.37M $110.76M $105.62M $103.68M $103.68M
-Accounts Receivable $94.91M $97.93M $91.87M $89.76M $89.76M
-Other Receivables $11.46M $12.84M $13.75M $13.92M $13.92M
Inventory $107.05M $103.36M $98.00M $92.43M $92.43M
Current Deferred Assets $53.73M $53.37M $53.41M $54.53M $54.53M
Other Current Assets $23.26M $26.57M $44.73M $42.54M $42.54M
Total Non-Current Assets $703.28M $700.55M $525.64M $526.71M $526.71M
Net PPE $117.27M $110.28M $102.30M $99.69M $99.69M
-Gross PPE $117.27M $110.28M $102.30M $197.53M $197.53M
Goodwill and Other Intangible Assets $566.87M $573.83M $406.55M $410.59M $410.59M
-Goodwill $344.96M $349.86M $251.66M $254.09M $254.09M
-Other Intangible Assets $221.91M $223.97M $154.89M $156.50M $156.50M
Non-Current Deferred Assets $1.27M $1.22M $1.14M $1.20M $1.20M
Other Non-Current Assets $17.87M $15.23M $15.66M $15.24M $15.24M
Total Liabilities $595.69M $626.35M $432.69M $436.56M $436.56M
Total Current Liabilities $76.66M $106.93M $92.70M $101.56M $101.56M
Payables $21.73M $26.45M $25.47M $23.53M $23.53M
-Accounts Payable $17.63M $20.87M $18.34M $16.04M $16.04M
-Total Tax Payable $4.10M $5.58M $7.13M $7.49M $7.49M
Current Accrued Expenses $26.14M $24.32M $23.69M $24.70M $24.70M
Short-Term Debt and Capital Lease Obligation $5.95M $5.92M $5.53M $5.38M $5.38M
-Current Capital Lease Obligation $5.95M $5.92M $5.53M $5.38M $5.38M
Other Current Liabilities $3.93M $32.40M $24.16M $25.47M $25.47M
Total Non-Current Liabilities $519.03M $519.42M $339.99M $335.01M $335.01M
Long Term Debt and Capital Lease Obligation $401.08M $402.05M $252.63M $252.24M $252.24M
-Long Term Debt $363.79M $363.42M $215.35M $215.11M $215.11M
-Long Term Capital Lease Obligation $37.29M $38.63M $37.28M $37.13M $37.13M
Non-Current Deferred Liabilities $35.41M $36.62M $37.38M $33.77M $33.77M
Other Non-Current Liabilities $82.55M $80.75M $49.99M $49.00M $49.00M
Total Equity $446.40M $445.59M $450.47M $448.23M $448.23M
Stockholders' Equity $446.40M $445.59M $450.47M $448.23M $448.23M
Capital Stock $503,000.00 $502,000.00 $500,000.00 $493,000.00 $493,000.00
-Common Stock $503,000.00 $502,000.00 $500,000.00 $493,000.00 $493,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $543.52M $535.80M $526.26M $516.60M $516.60M
Retained Earnings -$71.52M -$63.59M -$50.08M -$51.50M -$51.50M
Less: Treasury Stock -$14.65M -$14.65M -$14.65M -$14.65M -$14.65M
Gains/Losses Not Affecting Retained Earnings -$11.46M -$12.48M -$11.57M -$2.72M -$2.72M
-Accumulated Depreciation – – – -$97.84M -$97.84M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$4.56M -$1.27M $1.15M $39.88M $19.56M
Net cash flow from continuing operations -$4.56M -$1.27M $1.15M $39.88M $19.56M
Net Income from Continuing Operations -$7.93M -$13.51M $1.42M $9.77M $2.43M
Depreciation & Depletion & Amortization $7.34M $6.75M $6.34M $22.46M $5.76M
Deferred Tax $586,000.00 -$897,000.00 -$524,000.00 $37,000.00 $1.52M
Other Non-Cash Items $5.89M $6.16M $3.57M $4.83M $5.93M
Change in Working Capital -$18.07M -$9.24M -$19.13M -$22.16M $2.22M
-Change in Receivables $3.93M -$5.21M -$2.76M -$7.27M -$6.35M
-Change in Inventory -$5.66M -$4.37M -$6.38M -$15.28M -$3.71M
-Change in Prepaid Assets $760,000.00 -$3.99M -$1.29M -$1.80M $2.91M
-Change in Payables and Accrued Expense -$17.10M $4.33M -$8.70M $2.18M $9.38M
Net cash flow from investing -$13.01M -$129.41M -$10.50M -$42.04M -$30.51M
Net Cash Flow from Continuing Investing Activities -$13.01M -$129.41M -$10.50M -$42.04M -$30.51M
Capital Expenditure -$13.01M -$10.75M -$8.00M -$39.04M -$27.51M
Net Business Purchase and Sale $0.00 -$115.66M -$1.00M – –
Net Other Investing Changes $0.00 -$3.00M -$1.50M -$3.00M –
Financing Cash Flow -$11.28M $152.39M $463,000.00 $11.28M $2.43M
Net Cash Flow from Continuing Financing Activities -$11.28M $152.39M $463,000.00 $11.28M $2.43M
Net Issuance Payments Of Debt -$869,000.00 $148.01M -$577,000.00 -$2.46M -$858,000.00
Proceeds from Stock Option Exercised $1.50M $1.38M $1.25M $13.07M $3.46M
Net Other Financing Charges -$11.91M $3.00M -$210,000.00 $668,000.00 -$173,000.00
Ending Cash Balance $48.40M $77.32M $55.76M $64.91M $64.91M
Net Change in Cash -$28.85M $21.71M -$8.89M $9.12M -$8.52M
Beginning Cash Balance $77.32M $55.76M $64.91M $53.46M $73.43M
Effect of Exchange Rate Changes -$67,000.00 -$161,000.00 -$258,000.00 $2.32M -$1,000.00
Free Cash Flow -$17.57M -$12.01M -$6.85M $839,000.00 -$7.95M
Gain/Loss from Continuing Operations – – – -$4.34M -$3.50M
Net Common Stock Issuance – – – $0.00 –

Discussion

No comments yet — be the first to weigh in on AORT.

Sign in to join the discussion.

Scroll to Top